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Engineering the rRNA decoding site of eukaryotic cytosolic
ribosomes in bacteria
Abstract
Structural and genetic studies on prokaryotic ribosomes have provided important insights into
fundamental aspects of protein synthesis and translational control and its interaction with ribosomal
drugs. Comparable mechanistic studies in eukaryotes are mainly hampered by the absence of both
high-resolution crystal structures and efficient genetic models. To study the interaction of
aminoglycoside antibiotics with selected eukaryotic ribosomes, we replaced the bacterial drug binding
site in 16S rRNA with its eukaryotic counterpart, resulting in bacterial hybrid ribosomes with a fully
functional eukaryotic rRNA decoding site. Cell-free translation assays demonstrated that hybrid
ribosomes carrying the rRNA decoding site of higher eukaryotes show pronounced resistance to
aminoglycoside antibiotics, equivalent to that of rabbit reticulocyte ribosomes, while the decoding sites
of parasitic protozoa show distinctive drug susceptibility. Our findings suggest that phylogenetically
variable components of the ribosome, other than the rRNA-binding site, do not affect aminoglycoside
susceptibility of the protein-synthesis machinery. The activities of the hybrid ribosomes indicate that
helix 44 of the rRNA decoding site behaves as an autonomous domain, which can be exchanged
between ribosomes of different phylogenetic domains for study of function.
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ABSTRACT
Structural and genetic studies on prokaryotic
ribosomes have provided important insights into
fundamental aspects of protein synthesis and
translational control and its interaction with riboso-
mal drugs. Comparable mechanistic studies in
eukaryotes are mainly hampered by the absence of
both high-resolution crystal structures and efficient
genetic models. To study the interaction of amino-
glycoside antibiotics with selected eukaryotic ribo-
somes, we replaced the bacterial drug binding site
in 16S rRNA with its eukaryotic counterpart, result-
ing in bacterial hybrid ribosomes with a fully
functional eukaryotic rRNA decoding site. Cell-free
translation assays demonstrated that hybrid ribo-
somes carrying the rRNA decoding site of higher
eukaryotes show pronounced resistance to amino-
glycoside antibiotics, equivalent to that of rabbit
reticulocyte ribosomes, while the decoding sites of
parasitic protozoa show distinctive drug suscept-
ibility. Our findings suggest that phylogenetically
variable components of the ribosome, other than the
rRNA-binding site, do not affect aminoglycoside
susceptibility of the protein-synthesis machinery.
The activities of the hybrid ribosomes indicate
that helix 44 of the rRNA decoding site behaves as
an autonomous domain, which can be exchanged
between ribosomes of different phylogenetic
domains for study of function.
INTRODUCTION
Accurate decoding of genetic information is a crucial step
in protein synthesis. Genetic, biochemical and structural
data provide evidence for a functional role of ribosomal
RNA in mRNA decoding and tRNA selection (1–3).
The functional relevance of rRNA residues in
codon–anticodon recognition and stabilization is reﬂected
in their universal conservation throughout the three
phylogenetic domains of life. While this holds true for
most nucleotides in helices 18, 34 and 44 of the small
subunit rRNA that form the aminoacyl-tRNA acceptor
site (A site), critical variations have evolved between
diﬀerent phylogenetic domains, most prominent in helix
44, the penultimate stem of 16S rRNA (4). These
variations most likely account for a decoding region that
has been highly optimized in the context of evolutionary
diﬀerentiation.
Aminoglycosides are a class of structurally related
antibiotics which interfere with decoding by binding to
the A site of small subunit rRNA (5). These antibiotics
preferentially target prokaryotic over eukaryotic ribo-
somes and aﬀect protein synthesis by inducing codon
misreading and inhibiting tRNA translocation (6–8).
The binding site is located within a conserved loop of
helix 44, which in part shows phylogenetic sequence
variability, e.g. at position 1408 and at base pair
1409–1491 (9) (rRNA residues are numbered according
to Escherichia coli nomenclature; see also Figure 2).
Crystal structures of various bacterial 30S ribosomal
particles in complex with diﬀerent ligands, e.g. tRNA and
antibiotics, have revealed the molecular mechanisms of the
decoding step at atomic resolution (10,11). In the absence
of high-resolution X-ray crystal structures of eukaryotic
ribosomes, model oligonucleotides mimicking the riboso-
mal decoding site have been used for structural analysis
of the A site in human cytosolic ribosomes (12).
Site-directed mutagenesis has been used in prokaryotes
to study the functional relevance of individual drug–
nucleotide contacts in aminoglycoside–ribosome interac-
tion (13). A detailed analysis of the aminoglycoside
target site in ribosomes of higher and lower eukaryotes
is complicated by the complexity of eukaryotic rRNA
genetics. Genetic manipulation of the rRNA component
of eukaryotic ribosomes has proven exceedingly diﬃcult
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due to the problem of the high copy number of
corresponding operons. Higher eukaryotes have so far
resisted any genetic manipulation of their ribosomal
nucleic acids, virtually abolishing the possibility to test
hypotheses by experimentation. Even in lower eukaryotic
organisms, such as yeast, the presence of 100–200
tandemly repeated copies at the RDN locus, has made
genetic studies of rRNA diﬃcult (14–16).
The eukaryotic ribosome diﬀers signiﬁcantly from
the prokaryotic one (17). It is impossible to predict the
contribution of additional, phylogenetically diverse ribo-
somal elements and characteristics, as in the eukaryotic
ribosome, to aminoglycoside susceptibility. It is, for
instance, commonly assumed that translation in mamma-
lian cells functions with higher ﬁdelity than that of
bacteria (18). To address this question experimentally,
we have performed domain shuﬄing experiments in
rRNA. Using genetic techniques, we successfully engi-
neered a functionally critical domain in the ribosome by
replacing the bacterial A-site rRNA of helix 44 with its
counterpart from higher and lower eukaryotes. For
functional characterization of these hybrid ribosomes,
we studied their susceptibility to antibiotics targeting the
ribosomal A site and which are known to aﬀect bacterial
versus eukaryotic ribosomes to diﬀerent extents.
MATERIALS AND METHODS
Construction of the rrn plasmid exchange system
Starting with Mycobacterium smegmatis mc2-155 SMR5
(19), a single-rRNA allelic strain bearing a deletion of
5 kb in the chromosomal rrnA operon was constructed
by gene replacement. The deletion strategy for chromo-
somal rRNA operons is shown in Supplementary
Figure 1. Subsequently and following integration of the
rrnB-replacement vector into the chromosomal rrnB locus,
the strain was transformed with integration-proﬁcient
vector pMIH-rrnB2058G for rRNA complementation.
pMIH-rrnB2058G is a derivative of plasmid pMV361-
rrnB2058G (20), in which the kanamycin resistance cassette
has been replaced with a hygromycin resistance cassette.
Counterselection and genetic screening for deletion of the
chromosomal rrnB locus resulted in strain M. smegmatis
rrn pMIH-rrnB2058G bearing unmarked full deletions
of the chromosomal rrnA and rrnB loci. In this strain,
ribosomal RNA is exclusively transcribed from the
complementation vector (Figure. 1).
To establish a genetic system for eﬃcient plasmid
exchange, an integration-proﬁcient complementation
vector pMIG-rrnB-sacB was designed that carries the
rrnB wild-type operon, a gentamicin resistance cassette,
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Figure 1. Sequential strategy for the generation of a plasmid-rRNA exchange system. From top: Following deletion of chromosomal rrnA,
a complementation vector pMIH-rrnB2058G carrying a functional rrn operon was introduced to the chromosomal attB site. Subsequent deletion of
rrnB resulted in M. smegmatis rrnA rrnB attB::pMIH-rrnB2058G, in which ribosomal RNA is exclusively transcribed from the plasmid. From
there, a plasmid-rRNA exchange system was established by replacing pMIH-rrnB2058G with pMIG-rrnB-sacB. Transformation with hybrid rRNA
genes pMIH-rrnBhybrid and selection on sucrose resulted in M. smegmatis rrnA rrnB attB::pMIH-rrnBhybrid with homogenous populations
of hybrid ribosomes.
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and the sucrose sensitivity marker sacB. This vector was
used to replace pMIH-rrnB2058G in strain M. smegmatis
rrn pMIH-rrnB2058G, resulting in strain M. smegmatis
rrn pMIG-rrnB-sacB. The latter was used as plasmid
exchange system in which the rrnB wild-type operon can
be eﬃciently replaced with an rrnB mutant operon by
transformation and selection on sucrose-containing media
(Figure. 1).
Construction of mutant strains with hybrid ribosomes
Site-directed mutagenesis of rRNA genes was performed
by PCR mutagenesis as described previously (21). In
brief, hybrid rDNA oligonucleotides comprising the
eukaryotic helix 44 decoding site sequence were used for
gene ampliﬁcation. Using restriction endonuclease recog-
nition sites present in the operon, rRNA gene fragments in
plasmid pMIH-rrnB were replaced to construct pMIH-
rrnBhybrid, the plasmids coding for hybrid 16S rRNA
genes. Mycobacterium smegmatis rrn pMIG-rrnB-sacB
was transformed with the various pMIH-rrnBhybrid
constructs and selected on hygromycin plates containing
sucrose (Figure 1). Successful plasmid exchange was
controlled by sequence analysis.
Minimal inhibitory concentrations
Broth microdilution tests were performed in a microtiter
plate format as described previously (22). In brief,
bacterial strains were cultured on Luria–Bertani (LB)
agar plates at 378C. Freshly grown cultures were
resuspended in LB broth supplemented with 0.05% of
Tween 80, diluted to an absorbance at 600 nm of 0.025,
and incubated in the presence of 2-fold serial dilutions
of the following 2-deoxystreptamine aminoglycosides:
paromomycin, neomycin, geneticin (G418), gentamicin,
netilmicin, tobramycin and kanamycin A (Sigma). After
incubation at 378C for 72 h, the minimal inhibitory
concentration (MIC) was recorded as the lowest concen-
tration of drug inhibiting visible growth.
Ribosome purification
Approximately 8 g of wet bacterial cell mass were
resuspended in 25ml of homogenization buﬀer (HB;
20mM Tris–HCl pH 7.4, 100mM NH4Cl, 10.5mM
MgCl2, 0.5mM EDTA and 3mM 2-mercaptoethanol)
and lyzed with a French Pressure Cell (American
Instrument Company, Maryland) at 16 000 psi, as
described previously (23). The lysate was supplemented
with DNase (RQ1 RNase-free, Promega, 2 U per gram
cell mass), incubated on ice for 10min, and adjusted with
HB to a volume of 70ml. Pre-cooled alumina (1.5 g per
gram cell mass) was added to the cell lysate, stirred on ice
for 20min, and removed by low-speed centrifugation
(10min at 2000g; all centrifugations were performed at
48C). Cell debris was sedimented by centrifugation for
30min at 10 000g and the lysate was passed through a tea
ﬁlter. Centrifugation of the lysate for 60min at 32 500g
resulted in the S-30 supernatant. Sixteen milliliter portions
of the supernatant were layered on 9ml sucrose cushions
(SC; 20mM Tris–HCl pH 7.4, 350mM NH4Cl, 10.5mM
MgCl2, 0.5mM EDTA, 1.1M sucrose and 3mM
2-mercaptoethanol) and centrifuged for 15 h at 110 000g
(Beckman Coulter OptimaTM L-80 XP Ultracentrifuge) to
separate ribosomal particles from the S-100 supernatant.
The S-100 fraction was dialyzed for 24 h (6000–8000
MWCO, Spectra/Por, Serva) with three intermittent
changes of buﬀer A (50mM Tris–HCl pH 7.5, 70mM
NH4Cl, 30mM KCl and 7mM MgCl2), concentrated
(Viva spin, 10 000 MWCO, Viva Science), and stored at
808C. Ribosome pellets from the S-100 preparation were
resuspended in washing buﬀer (WB; 20mM Tris–HCl pH
7.4, 350mM NH4Cl, 10.5mMMgCl2, 0.5mM EDTA and
7mM 2-mercaptoethanol) and passed twice through
sucrose cushions (6 h at 180 000g and 16 h at 83 000g).
The ﬁnal ribosome pellets were resuspended in buﬀer A,
incubated for 30min at 48C, dispensed into aliquots, and
stored at 80C after shock freezing in liquid nitrogen. 70S
ribosome concentrations were determined by absorption
measurements on the basis of 23 pmol per A260 unit.
Qualitative evaluation of ribosome preparations
Integrity of 70S ribosomes was determined by analytical
ultracentrifugation (14 h at 70 000g) through a 10–40%
sucrose gradient in both association buﬀer (buﬀer A) and
dissociation buﬀer (50mM Tris–HCl pH 7.5, 70mM
NH4Cl and 30mM KCl). 70S, 50S and 30S ribosome
fractions in diﬀerent gradient layers were detected and
quantiﬁed by absorption at 254 nm. Functional activity of
puriﬁed ribosomes was determined by assessing their
capacity to form initiation complexes. 70S ribosomes
(0.5 mM) were incubated in buﬀer A with m022 SD-MFTI-
mRNA at 1.5 mM (50-GGCAAGGAGGUAAAUAAUG
UUCACGAUC-30; obtained from Dharmacon), initiation
factors (IF) 1 and 3 from M. smegmatis, IF-2 from E. coli
(1mM each), GTP (1mM), and [3H]-fMet-tRNAfMet
(1mM) for 60min at 378C; puriﬁed tRNA and IF2
from E. coli were a kind gift from Marina Rodnina.
The initiation complexes formed were bound to nitrocel-
lulose ﬁlters (Sartorius, pore size 0.45mm), washed with
15ml cold buﬀer A, dissolved in 10ml scintillation
cocktail (Filtersafe, Zinsser Analytic) and quantiﬁed in a
Liquid Scintillation Analyzer (Tri-Carb 2900 TR,
PerkinElmer).
Cell-free (UUU)12 translation assays
Cell-free translation reactions in buﬀer A (pH 7.5) were
prepared on ice and contained M. smegmatis tRNAbulk
(0.5mg/ml), amino acids mixture (30 mM each) lacking
phenylalanine and/or leucine, 10% (v/v) S100 extract,
energy mix [DTT (1mM), GTP (1mM), ATP (4mM),
PEP (5mM)], pyruvate kinase (0.1mg/ml), and polya-
mines [spermidine (2mM) and putrescine (8mM)].
The reaction mixture was preincubated with radiolabeled
phenylalanine and/or leucine (30 mM; obtained from
Amersham) at 378C for 15min. The translation reaction
was started by addition of ribosomes to a ﬁnal concentra-
tion of 0.25 mM and (UUU)12-mRNA (50-GCGGCAA
GGAGGUAAAUA AUG (UUU)12 UAA GCAGG-3
0,
obtained from Dharmacon) to 1 mM; serially diluted
aminoglycoside antibiotics were added simultaneously.
Following incubation at 378C for 60min, the reaction was
Nucleic Acids Research, 2007 3
stopped by addition of KOH to 0.5M and subsequent
hydrolysis at 378C for 30min. Synthesized polypeptides
were precipitated with 200 ml of 5% tri-chloro-acetic acid
(TCA) for 10min on ice and bound to nitrocellulose ﬁlters
(Sartorius, pore size 0.45mm). Filter-bound polypeptides
were washed with cold 30% 2-propanol and quantiﬁed
in 10ml of scintillation cocktail. Data analysis was
performed with Prism (GraphPad Software Inc.). Best-ﬁt
nonlinear regression was used to deﬁne the 100% value of
polypeptide synthesis and to calculate the aminoglycoside
IC50 values of dose-dependent inhibition (Figure 3
and Table 2).
Cell-free luciferase translation assays
Puriﬁed 70S hybrid ribosomes were used in a coupled
transcription–translation reaction of ﬁreﬂy luciferase
(plasmid pBESTluc, Promega). A typical reaction
(15ml volume) contained 0.25 mM 70S ribosomes, 300 ng
DNA, 40% (v/v) of M. smegmatis S100 extract, 100 mM
amino acid mixture, and RNasin (40 U, Promega). rNTPs,
tRNAs and energy were supplied by addition of commer-
cial S30 Premix Without Amino Acids (Promega). Serially
diluted aminoglycosides were added and the reaction
mixture was incubated at 378C for 60min. The reaction
was stopped on ice, 100 ml of luciferase assay substrate
(Promega) was added, and the bioluminescence was
measured in a luminometer (Bio-Tek instruments,
FLx800). Data analysis was performed with Prism
(GraphPad Software Inc.). Best-ﬁt nonlinear regression
was used to deﬁne the 100% value of luciferase synthesis
and to calculate the aminoglycoside IC50 values of dose-
dependent inhibition (Figure 4 and Table 3).
Rabbit reticulocyte translation assays
Cytosolic ribosomes present in commercially available
rabbit reticulocyte lysate (Promega) were used for in vitro
translation of a ﬁreﬂy luciferase control mRNA
(Promega). A standard 30 ml reaction contained 20 ml
reticulocyte lysate, 500 ng of luciferase mRNA, an amino
acid mixture (100 mM each), and RNasin. Serially diluted
aminoglycosides were added and the reaction mixture was
incubated at 308C for 90min. After incubation, 100 ml
of luciferase assay substrate (Promega) was added and
luciferase activity was determined.
RESULTS AND DISCUSSION
The two chromosomal rrn operons in M. smegmatis were
inactivated to produce a strain in which ribosomal RNA
is exclusively transcribed from plasmid-encoded rRNA
genes. Operon inactivation was achieved by means of
unmarked deletion mutagenesis spanning the complete
rRNA gene sequences and part of the promoter region
(Supplementary Figure 1). For complementation, a fully
functional wild-type rrnB operon encompassing promoter
and termination sequences was cloned into the integra-
tion-proﬁcient plasmid pMIG-sacB. In M. smegmatis
rrn pMIG-sacB-rrnB, the wild-type rRNA operon
carried on pMIG-sacB is eﬃciently replaced with a
mutant rRNA operon by plasmid exchange following
transformation with integration-proﬁcient plasmid pMIH-
rrnBmut (for details, see the Materials and Methods section
and Figure 1). The rRNA plasmid exchange system was
used to replace the bacterial 16S rRNA helix 44 within the
decoding region with its homologous structures from
parasitic kinetoplastid protozoa. The kinetoplastid genera
Leishmania and Trypanosoma comprise species that are
responsible for leishmaniasis and trypanosomiasis,
diseases that are widespread in many tropical and sub-
tropical countries. The insect trypanosome Blastocrithidia
is characterized by an rRNA decoding site with an adenine
at the position homologous to 16S rRNA residue 1408,
and therefore represents a very rare trait within the
eukaryotic domain. We also constructed human–bacterial
hybrid ribosomes by introducing the human helix 44
rRNA homolog into functional ribosomes of strain
M. smegmatis rrnB by a method described previously
(13). Both approaches resulted in bacterial mutant strains
with homogenous populations of hybrid ribosomes in
which a 34 nucleotide portion of helix 44 was substituted
with its counterpart of eukaryotic small-subunit rRNA
(Figure 2). Together with A-site residues in helices 18, 34
and 44 that are universally conserved throughout the
phylogenetic domains, the engineered decoding site
resembles that of eukaryotic cytosolic ribosomes.
Engineering the eukaryotic decoding sites into bacterial
ribosomes had relatively little eﬀect on cell growth, with
only slightly increased generation times as compared to
wild-type cells (generation times: wild-type 3.7 0.3 h;
Leishmania hybrids 4.8 0.5 h; Blastocrithidia hybrids
4.2 0.1 h; H. sapiens hybrids 5.1 0.6 h).
A bacterial oligoribonucleotide analog of 16S rRNA
helix 44 has been shown to interact with both antibiotic
and RNA ligands of the 30S subunit in a manner that
correlates with normal subunit function (24). Since the
decoding-site rRNA in the hybrid ribosomes is identical to
that of eukaryotic ribosomes, the hybrid ribosomes may
serve as a model to investigate speciﬁc features associated
with the eukaryotic A-site rRNA structure. Towards this
end, we investigated the susceptibility of the hybrid
ribosomes to the 2-deoxystreptamine antibiotics paromo-
mycin, neomycin, geneticin (G418), gentamicin, netilmi-
cin, tobramycin and kanamycin A (see Supplementary
Figure 2 for chemical structures). In MIC assays, which
determine growth inhibition at the whole cell level,
M. smegmatis mutants carrying human–bacterial hybrid
ribosomes were highly resistant to all aminoglycoside
antibiotics tested except for geneticin (Table 1). Relative
resistance of the human hybrids to geneticin, calculated
as the ratio of mutant to wild-type MIC, was 8 to 16 as
compared to  1024 for paromomycin, neomycin, genta-
micin, netilmicin, tobramycin, and kanamycin. The
Leishmania hybrids showed high-level resistance to
neomycin, gentamicin, netilmicin, tobramycin and kana-
mycin, with relative resistance levels of 1024. However,
the Leishmania hybrids showed distinct susceptibility to
paromomycin and geneticin, i.e. aminoglycosides with
a hydroxyl group at position 60 of ring I. Mycobacterium
smegmatis hybrids with a Blastocrithidia decoding region
were susceptible to all aminoglycoside antibiotics;
the minimal inhibitory concentrations of the 4,6- and
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4,5-disubstituted deoxystreptamines against
Blastocrithidia hybrids were similar to those observed for
the wild-type M. smegmatis strain (Table 1).
To analyze the antibiotic eﬀects on translation in more
detail, we determined the IC50 values for selected
aminoglycosides in (UUU)12-mRNA-directed phenylala-
nine incorporation in cell-free translation assays. In vitro
translation assays were established with puriﬁed 70S
ribosomes of wild-type and mutant M. smegmatis strains.
A polyphenylalanine mRNA with a ribosomal-binding
site, twelve consecutive (UUU) triplets coding for
phenylalanine, and a stop codon was used to assess
aminoglycoside-induced inhibition of [14C]-phenylalanine
incorporation in translating wild-type and hybrid ribo-
somes. Bacterial wild-type ribosomes were highly suscep-
tible to all aminoglycosides tested, with IC50 values for
poly-Phe synthesis below 3 mM (Figure 3 and Table 2).
Hybrid ribosomes with a Blastocrithidia decoding region
were likewise susceptible to low aminoglycoside concen-
trations. In contrast, hybrid ribosomes with the human
decoding site were resistant, exhibiting IC50 values that are
more than 500-fold higher than those observed in bacterial
wild-type ribosomes. Leishmania hybrid ribosomes were
resistant to all aminoglycosides tested except paromomy-
cin. In order to assess aminoglycoside-stimulated mis-
reading (25) in hybrid ribosomes, paromomycin was used
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Figure 2. 16S rRNA sequence within helix 44 of M. smegmatis wild-type and hybrid ribosomes after transplanting the A-site rRNA of eukaryotic
ribosomes. (A) Mycobacterium smegmatis. (B) Human–bacterial hybrid ribosomes. (C) Hybrid ribosomal RNA containing the decoding-site rRNA
of the protozoan Leishmania, which is also identical to Trypanosoma; and (D) Blastocrithidia. Base substitutions rendering the bacterial 16S rRNA
eukaryotic are depicted in blue; the transplanted region is boxed. rRNA residues are numbered according to the nucleotide numbering used in E. coli
16S rRNA.
Figure 3. Kanamycin-induced inhibition of polypeptide synthesis using (UUU)12-directed phenylalanine incorporation. (A) Homo sapiens cytosolic
hybrid ribosomes (closed circles) versus M. smegmatis wild-type ribosomes (open circles). (B) Leishmania (closed squares) versus Blastocrithidia (open
squares) hybrid ribosomes. The relative amount of [14C]-phenylalanine incorporated by 5 pmol of puriﬁed 70S ribosomes after 60min. incubation in
the presence of varying concentrations of kanamycin A is shown. SEs are indicated. The corresponding IC50 values for kanamycin A and selected
aminoglycoside antibiotics are given in Table 2.
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to measure drug-induced incorporation of leucine in a
cell-free (UUU)12 translation assay. In line with the other
assays used to determine ribosomal drug susceptibility,
the Leishmania hybrids were signiﬁcantly more susceptible
to paromomycin-induced mistranslation than the human
hybrids (data not shown).
We next wished to validate the hybrid ribosome
approach by comparing the human–bacterial hybrid
ribosomes to rabbit reticulocyte ribosomes (the decoding-
site rRNA of human cytosolic ribosomes is identical to
that of most vertebrates, including rabbit). In addition,
with a view to deﬁne the selectivity of aminoglycoside
compounds for protozoan versus human ribosomes more
accurately, we wished to use an assay which is not limited
by its sensitivity. Note that both the whole-cell determina-
tion of minimal inhibitory concentrations (MIC; Table 1)
and the (UUU)12 assay using puriﬁed ribosomes (Table 2)
are limited by the amount of drug which can be applied.
Towards this end we analyzed synthesis of luciferase based
upon a coupled transcription–translation assay. Figure 4
shows the eﬀect of paromomycin on protein synthesis
in bacterial versus human–bacterial hybrid ribosomes
and compared to rabbit reticulocyte ribosomes translating
a luciferase mRNA. The paromomycin concentration
required to inhibit synthesis of active luciferase in human-
hybrid ribosomes to 50% (IC50) closely resembled the IC50
Table 3. Aminoglycoside-induced inhibition of luciferase synthesis
Compound IC50 (mM)
a
Mycobacterium
smegmatis
Homo sapiens Leishmania
Trypanosoma
Blastocrithidia Rabbit reticulocyte
lysateb
Paromomycin 0.03 4.7 0.18 0.05 9.2
Neomycin 0.04 13 6.7 0.05 18
Geneticin 0.03 0.8 0.02 0.02 0.2
Netilmicin 0.05 64 127 0.11 58
Tobramycin 0.02 21 60 0.05 38
Kanamycin A 0.05 116 204 0.03 67
aAminoglycoside concentrations required to inhibit synthesis of active luciferase to 50 percent (IC50). Inhibition kinetics are exempliﬁed by the graphs
for paromomycin presented in Figure 4. Best-ﬁt nonlinear regression was used to deﬁne the 100% value and to calculate the IC50.
bThe rRNA decoding region of rabbit reticulocyte ribosomes is identical to that of human cytosolic ribosomes shown in Figure 2B.
Figure 4. Paromomycin-induced inhibition of protein synthesis
measured as luciferase activity in cell-free translation assays of ﬁreﬂy
luciferase mRNA. Rabbit reticulocyte (closed triangles) versus human-
bacterial hybrid (closed circles) and wild-type M. smegmatis (open
circles) ribosomes; error bars represent the SEM (n=3). The
corresponding IC50 values for paromomycin and the aminoglycosides
tested are given in Table 3.
Table 2. Aminoglycoside-induced inhibition of (UUU)12-directed
phenylalanine incorporation
Compound IC50 (mM)
a
Mycobacterium
smegmatis
Homo
sapiens
Leishmania
Trypanosoma
Blastocrithidia
Paromomycin 0.9 >500 96 2.7
Neomycin 0.4 >500 >500 0.7
Gentamicin 0.7 >500 >500 0.7
Netilmicin 0.7 >500 >500 1.1
Tobramycin 1.0 >500 >500 2.3
Kanamycin A 2.5 >500 >500 7.5
aAminoglycoside concentrations required to inhibit [14C]-phenylalanine
incorporation to 50 percent (IC50). Inhibition kinetics are exempliﬁed
by the graphs for kanamycinA presented in Figure 3. Best-ﬁt nonlinear
regression was used to deﬁne the 100% value and to calculate the IC50.
An antibiotic concentration of 1 mM corresponds to approximately four
aminoglycoside molecules per ribosome.
Table 1. Activity of aminoglycoside antibiotics against cells carrying
hybrid ribosomes
Compound MIC (mg/ml)
Mycobacterium
smegmatis
Homo
sapiens
Leishmania
Trypanosoma
Blastocrithidia
Paromomycin 1 1024 128 4
Neomycin 0.5 >1024 >1024 1
Geneticin 8 128 4 4
Gentamicin 1 >1024 >1024 1
Netilmicin 2 >1024 >1024 8
Tobramycin 1 1024 1024 2
Kanamycin A 1 >1024 >1024 1
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in rabbit reticulocyte lysate. In fact, the IC50 values of the
human hybrid ribosomes are virtually identical to the IC50
values determined for rabbit cytosolic ribosomes for all
aminoglycosides tested in this study (Table 3). In contrast,
the IC50 values in bacterial ribosomes were two to three
orders of magnitude lower. Thus, transplanting helix 44 of
the eukaryotic decoding region into bacterial ribosomes
testiﬁed to be a valid approach for studying the speciﬁcity
of aminoglycoside antibiotics, compounds that selectively
aﬀect prokaryotic versus eukaryotic ribosomes.
Analysis of aminoglycoside-induced inhibition of
luciferase synthesis in Leishmania hybrid ribosomes and
comparison to human hybrid ribosomes also allowed
quantifying the diﬀerences in drug susceptibility.
Leishmania hybrid ribosomes are 20- to 30-fold
more susceptible to the 4,5-disubstituted aminoglycoside
paromomycin than human hybrid ribosomes. In line with
the results from MIC determinations (Table 1) and
aminoglycoside-induced inhibition of (UUU)12-driven
phenylalanine incorporation (Table 2), there is a signiﬁcant
diﬀerence in drug susceptibility between Leishmania hybrid
and human hybrid ribosomes for aminoglycosides with a
60-hydroxyl group. This is in contrast to aminoglycosides
with a 60-amino group where no such diﬀerence is present.
The basic mechanisms of translation of mRNA to
protein are conserved throughout all organisms (17,26).
Experimental data suggest that the selectivity of amino-
glycoside antibiotics for bacterial ribosomes is due to
deﬁned phylogenetic variations of ribosomal RNA in an
otherwise highly conserved binding site (13). The results
obtained with the hybrid ribosomes are in excellent
agreement with the drug susceptibilities determined in
rabbit reticulocyte lysate (Table 3) and with data reported
in the literature on complete eukaryotic ribosomes (25,27),
demonstrating that the model system adequately reﬂects
the situation in eukaryotic cytosolic ribosomes. Drugs
targeting protein synthesis are infrequently used for
treatment of infections with lower eukaryotes such as
protozoan parasites, helminths or fungi, although the
potential for selective activity appears to exist (28–33).
Using various assays of drug activity, we demonstrated
that the 4,5-disubstituted aminoglycoside paromomycin
exhibits a distinct activity towards hybrid ribosomes
carrying the cytosolic decoding site of Leishmania and
Trypanosoma. These results provide an explanation for the
activity of paromomycin in treatment of leishmaniasis
(34,35), by pointing to the cytosolic ribosome as a drug
target. Little treatment options involving quite toxic
drugs, such as the trivalent arsenic compound melarso-
prol, exist for late stage T. brucei rhodiense sleeping
sickness (36). The availability of compounds with anti-
trypanosomal activity would be most signiﬁcant, if only as
second-line option for patients who experience relapse.
Deﬁned point mutations have been introduced pre-
viously into the bacterial rRNA A site to study individual
drug—nucleotide interactions of aminoglycosides (13).
These studies demonstrated the role of nucleotides 1408,
1409 and 1491 in drug binding. A base substitution of
adenine at position 1408 with a guanine interrupts the
pseudo-base-pair formation of the adenine with ring I of
the disubstituted 2-deoxystreptamines and alterations of
the 1409–1491 bp interfere with the stacking interaction
between 1491 and ring I. Our study complements this
reductionistic approach by transferring the complete
eukaryotic binding site into bacterial ribosomes. Given
the complex structure of the ribosome and its various
components that contribute to translational ﬁdelity, e.g.
ribosomal proteins S4, S5 and S12 (3), it is remarkable
that a hybrid bacterial ribosome carrying the eukaryotic
H44 shows a drug-susceptibility pattern identical to that
of complete rabbit reticulocyte ribosomes. From this we
conclude that additional phylogenetically variable riboso-
mal structures do not aﬀect aminoglycoside susceptibility
of the complete eukaryotic ribosome. In line with previous
ﬁndings (13,37–39), a more general picture emerges, where
ribosomes with a 1408 guanine in small subunit rRNA are
resistant to aminoglycosides carrying an amino group at
position 60 of ring I (neomycin, gentamicin, netilmicin,
tobramycin, kanamycin), while A sites with a non-
canonical base-pair interaction between residues 1409
and 1491 are predominantly resistant to geneticin and
paromomycin, drugs which carry a hydroxyl group at the
60 position of ring I. Together, these results suggest that
paromomycin and geneticin have a speciﬁc activity against
ribosomes that are characterized by a canonical 1409–
1491 bp; that neomycin, gentamicin, netilmicin, tobramy-
cin and kanamycin are active against ribosomes with a
1408 adenine; and that metazoan cytosolic ribosomes are
generally resistant to 2-deoxystreptamines.
Successful crystallizations of the ribosome and ribo-
some–drug complexes have initiated a rebirth of interest in
the ribosome as drug target (40–43). Apparently, helix 44
of the rRNA decoding A site behaves as an autonomous
domain, which can be dissected from the remaining part of
the ribosome and shuﬄed between ribosomes of diﬀerent
phylogenetic domains in vivo while retaining its functional
characteristics. It is likely that this possibility will help
to study mechanisms of the various eukaryotic rRNA
decoding sites in the future and to test hypotheses built
upon X-ray structures. The construction of hybrid
ribosomes, as demonstrated in this study, should also
help characterizing the speciﬁcity of ribosomal inhibitors
already available and of future compounds to come.
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